‘”Why me, why now?” Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection [PDF]
, 2016 David M. Lowe +3 more
core +1 more source
Fatal X-linked agammaglobulinemia complicated by septic shock: a case report and comprehensive review of novel BTK mutations. [PDF]
Front ImmunolWu P, You W, Liu W, Luo N, Xu J.
europepmc +1 more source
Development of a Partial Proteolysis Targeting Chimera Library Based on Achiral Cereblon E3 Ligase Ligands and its Application for Bruton's Tyrosine Kinase Degraders. [PDF]
ChemMedChemAlmodóvar-Rivera CM +5 more
europepmc +1 more source
A pharmacovigilance study of Bruton's tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase. [PDF]
Front ImmunolQu H +7 more
europepmc +1 more source
Exploratory Covalent Docking of Michael-Acceptor Natural Products at Reactive Cysteines in Cancer Tyrosine Kinases. [PDF]
Int J Mol SciLobo F +5 more
europepmc +1 more source
Case Report: Preserved umbilical cords underscore family histories of inborn errors of immunity. [PDF]
Front ImmunolNishimura M +4 more
europepmc +1 more source
Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting. [PDF]
Future OncolShah BD, Xue M, Furnback W, Yang K.
europepmc +1 more source
BTK inhibitors potently impair platelet aggregation as a class effect independent of BTK specificity or dose in CLL and MCL. [PDF]
J Clin Exp HematopKojima K +4 more
europepmc +1 more source
Composition of precursor B-cell compartment in bone marrow from patients with X-linked agammaglobulinemia compared with healthy children [PDF]
, 2002 Bitter, Marieke +6 more
core +5 more sources